Evidence map›Paper›PMID 35752612›Full record

ReviewSignal transduction and targeted therapy2022

Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.

Shugang Qin, Wen Xiao, Chuanmin Zhou, Qinqin Pu, Xin Deng, Lefu Lan, Haihua Liang, Xiangrong Song, Min Wu

Open access · goldAbstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 759 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
759citing papers in PubMed, 1 pooled it
85.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

759 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,266 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Multifaceted effects ofVirulence · 2026
    Article
  4. Article
  5. Review
  6. High resolution cryo-EM structure of theJournal of structural biology: X · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

699 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Shugang Qin *Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wen Xiao *Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Chuanmin Zhou *State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, 430071, P.R. China.
Qinqin PuDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, 58203, USA.
Xin DengDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong, People's Republic of China.
Lefu LanState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.ORCID 0000-0002-5551-5496
Haihua LiangCollege of Life Sciences, Northwest University, Xi'an, ShaanXi, 710069, China.
Xiangrong SongDepartment of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China. songxr@scu.edu.cn.ORCID 0000-0002-2853-2696
Min WuDepartment of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China. min.wu@und.edu.ORCID 0000-0003-1205-982X
Sichuan University · CNUniversity of North Dakota · USChinese Academy of Sciences · CNCity University of Hong Kong · HKNorthwest University · CN

Funding

Lung innate immunity against bacterial infectionR01AI109317 · NIAID · UNIVERSITY OF NORTH DAKOTA · PI WU, MIN · 2014 to 2018
$1.7M
Long noncoding RNAs interact with miRNAs to regulate inflammatory responseR01AI138203 · NIAID · UNIVERSITY OF NORTH DAKOTA · PI COMBS, COLIN K · 2018 to 2021
$1.4M
NIAID NIH HHS R01 AI109317NIAID NIH HHS R01 AI138203NIH HHS R01 AI138203-3
6 · The paper itself

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic pathogen that infects patients with cystic fibrosis, burn wounds, immunodeficiency, chronic obstructive pulmonary disorder (COPD), cancer, and severe infection requiring ventilation, such as COVID-19. P. aeruginosa is also a widely-used model bacterium for all biological areas. In addition to continued, intense efforts in understanding bacterial pathogenesis of P. aeruginosa including virulence factors (LPS, quorum sensing, two-component systems, 6 type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation), rapid progress has been made in further studying host-pathogen interaction, particularly host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc. Furthermore, numerous technologic advances, such as bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy, have been used to improve our understanding of P. aeruginosa pathogenesis and host defense. Nevertheless, much remains to be uncovered about interactions between P. aeruginosa and host immune responses, including mechanisms of drug resistance by known or unannotated bacterial virulence factors as well as mammalian cell signaling pathways. The widespread use of antibiotics and the slow development of effective antimicrobials present daunting challenges and necessitate new theoretical and practical platforms to screen and develop mechanism-tested novel drugs to treat intractable infections, especially those caused by multi-drug resistance strains. Benefited from has advancing in research tools and technology, dissecting this pathogen's feature has entered into molecular and mechanistic details as well as dynamic and holistic views. Herein, we comprehensively review the progress and discuss the current status of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection, which point out new directions for future investigation and add to the design of novel and/or alternative therapeutics to combat this clinically significant pathogen.

Indexed as

COVID-19Pseudomonas InfectionsAnimalsDrug Resistance, MicrobialHumansMammalsPseudomonas aeruginosaTechnologyVirulence FactorsVirulence Factors

Identifiers

PMID35752612
PMCPMC9233671
OpenAlexW4283522546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.